Adaptimmune Therapeutics plc

Adaptimmune Therapeutics plcverified

ADAP

Price:

$0.937

Market Cap:

$239.40M

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4 that is in phase II clinical trials with SPEARHEAD-1 for synovial sarcoma and myxoid round cell liposarcoma indications (MRCLS); in phase II clinical trials with SPEARHEAD-2 for patients with head and neck cancer; and in phase I clinical trials for urothelial, melanoma, head and neck, ovarian, non-small cell lung, esophageal and gastric, synovial sar...[Read more]

Industry

Biotechnology

IPO Date

2015-05-06

Stock Exchange

NASDAQ

Ticker

ADAP

The PE Ratio as of June 2024 (TTM) for Adaptimmune Therapeutics plc (ADAP) is -1.28

According to Adaptimmune Therapeutics plc’s latest financial reports and current stock price. The company's current PE Ratio is -1.28. This represents a change of -10.63% compared to the average of -1.43 of the last 4 quarters.

Adaptimmune Therapeutics plc (ADAP) Historical PE Ratio (quarterly & annually)

How has ADAP PE Ratio performed in the past?

The mean historical PE Ratio of Adaptimmune Therapeutics plc over the last ten years is -59.69. The current -1.28 PE Ratio has changed 114.43% with respect to the historical average. Over the past ten years (40 quarters), ADAP's PE Ratio was at its highest in in the September 2018 quarter at 64.49. The PE Ratio was at its lowest in in the September 2014 quarter at -520.16.

Quarterly (TTM)
Annual

Average

-59.69

Median

-4.93

Minimum

-534.98

Maximum

-0.92

Adaptimmune Therapeutics plc (ADAP) PE Ratio by Quarter and Year

Discovering the peaks and valleys of Adaptimmune Therapeutics plc PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 542.76%

Maximum Annual PE Ratio = -0.92

Minimum Annual Increase = -94.32%

Minimum Annual PE Ratio = -534.98

Quarterly (TTM)
Annual
YearPE RatioChange
2023-1.39-1.94%
2022-1.42-61.51%
2021-3.70-37.39%
2020-5.90542.76%
2019-0.92-84.34%
2018-5.86-30.00%
2017-8.38109.12%
2016-4.01-86.82%
2015-30.38-94.32%
2014-534.98-33.36%

Adaptimmune Therapeutics plc (ADAP) Average PE Ratio

How has ADAP PE Ratio performed in the past?

The current PE Ratio of Adaptimmune Therapeutics plc (ADAP) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

3-year avg

-2.17

5-year avg

-2.67

10-year avg

-59.69

Adaptimmune Therapeutics plc (ADAP) PE Ratio vs. Peers

How is ADAP’s PE Ratio compared to its peers?

Adaptimmune Therapeutics plc’s PE Ratio is greater than Stoke Therapeutics, Inc. (-6.65), less than Homology Medicines, Inc. (-0.01), greater than Black Diamond Therapeutics, Inc. (-3.55), greater than Harpoon Therapeutics, Inc. (-2.94), greater than Mereo BioPharma Group plc (-84.65), less than Pieris Pharmaceuticals, Inc. (-0.74), greater than PDS Biotechnology Corporation (-2.12), less than Leap Therapeutics, Inc. (-1.05), less than Affimed N.V. (-1.02), greater than Corvus Pharmaceuticals, Inc. (-3.81), less than Aptose Biosciences Inc. (-0.24), greater than Nkarta, Inc. (-2.47), greater than Agios Pharmaceuticals, Inc. (-6.81), greater than Pliant Therapeutics, Inc. (-3.95), less than Adicet Bio, Inc. (-0.75), greater than MiNK Therapeutics, Inc. (-1.53), greater than ImmunoGen, Inc. (-122.93), less than Sangamo Therapeutics, Inc. (-0.23),

Build a custom stock screener for Adaptimmune Therapeutics plc (ADAP) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Adaptimmune Therapeutics plc using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Adaptimmune Therapeutics plc (ADAP) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Adaptimmune Therapeutics plc or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the PE Ratio?

How can you use the PE Ratio?

What is Adaptimmune Therapeutics plc's PE Ratio?

How is the PE Ratio calculated for Adaptimmune Therapeutics plc (ADAP)?

What is the highest PE Ratio for Adaptimmune Therapeutics plc (ADAP)?

What is the 3-year average PE Ratio for Adaptimmune Therapeutics plc (ADAP)?

What is the 5-year average PE Ratio for Adaptimmune Therapeutics plc (ADAP)?

How does the current PE Ratio for Adaptimmune Therapeutics plc (ADAP) compare to its historical average?